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Introduction {#osp446-sec-0005}
============

Obesity affects one‐third (34.9%) of adults in the USA [1](#osp446-bib-0001){ref-type="ref"}. Obesity is associated with an increased risk of a variety of diseases, including type 2 diabetes, dyslipidemia, hypertension, sleep apnea, osteoarthritis, cardiovascular disease and respiratory diseases [2](#osp446-bib-0002){ref-type="ref"}, as well as several types of cancers [3](#osp446-bib-0003){ref-type="ref"}. Obesity also poses a high economic burden on society, with medical costs associated with obesity totaling approximately \$147bn per year in the USA [4](#osp446-bib-0004){ref-type="ref"}.

The primary approach for obesity management and control is a change in lifestyle, but the benefits of pharmacotherapy for weight loss also have been demonstrated in clinical trials [5](#osp446-bib-0005){ref-type="ref"}, [6](#osp446-bib-0006){ref-type="ref"}. The combined use of lifestyle modification and pharmacotherapy may work better in achieving clinically meaningful weight‐loss goal [7](#osp446-bib-0007){ref-type="ref"}. According to the 2013 American Heart Association/American College of Cardiology/The Obesity Society guidelines [2](#osp446-bib-0002){ref-type="ref"}, pharmacotherapy as an adjunctive treatment to comprehensive lifestyle changes may be an option for motivated patients with a body mass index (BMI) ≥30 kg m^−2^ or ≥27 kg m^−2^ with ≥1 obesity‐associated comorbidity. However, data are limited on the characteristics of real‐world patients eligible for adjunctive pharmacotherapy and the predictors of adjunctive pharmacotherapy use. Such data may help develop effective strategies for weight‐loss management and control. An analysis was thus conducted to describe the characteristics of real‐world patients potentially eligible for adjunctive pharmacotherapy for weight loss and to identify the predictors of adjunctive pharmacotherapy use in the primary care setting in the USA.

Methods {#osp446-sec-0006}
=======

Study population {#osp446-sec-0007}
----------------

A retrospective analysis was conducted using data from the GE Centricity® database, a de‐identified longitudinal ambulatory care electronic medical record database with approximately 38 million patient records mainly from primary care providers in 49 states and Washington, DC, in the USA. At the time of the analysis, data were available through 30 September 2013. The distribution of age, gender and race in this database is generally similar to the US population.

Patients with BMI records were identified between 1 October 2002 and 30 September 2011 (index period). Patients were eligible if they had a BMI ≥30 kg m^−2^ or BMI ≥27 to \<30 kg m^−2^ with ≥1 obesity‐associated comorbidity (hypertension, dyslipidemia, or type 2 diabetes); were aged ≥18 years at the index date; had ≥12 months of continuous enrollment before and on the index date (baseline period) and had ≥12 months of continuous follow‐up after the index date. The index date was defined as the date of the first BMI value of ≥30 kg m^−2^ or BMI ≥27 to \<30 kg m^−2^ with ≥1 obesity‐associated comorbidity recorded during the index period. For patients with BMI values of both ≥30 kg m^−2^ and BMI ≥27 to \<30 kg m^−2^ with ≥1 obesity‐associated comorbidity, BMI of ≥30 kg m^−2^ took precedence. Patients\' records with extreme values of height (\<3 or ≥8 ft), weight (\<50 or ≥650 Ib), or BMI (\<12 or ≥100 kg m^−2^), or with extreme laboratory values were excluded from the analysis.

Study covariates {#osp446-sec-0008}
----------------

Patient characteristics included demographic variables collected at index (age, gender, race, geographic region and insurance); anthropometric and lifestyle variables within 12 months prior to or on the index date (weight \[kg\], BMI \[weight in kg/height in m^2^\] and smoking status); comorbid conditions within 12 months before or on the index date (hypertension, dyslipidemia, depression, anxiety, sleep apnea, gastroesophageal reflux disease \[GERD\] and asthma); comorbid conditions any time before or on the index date (type 2 diabetes, osteoarthritis, coronary heart disease, congestive heart failure, cardiac dysrhythmia, stroke, chronic kidney disease and chronic obstructive pulmonary disease); comedications within 12 months before or on the index date (anti‐diabetic drugs, anti‐hypertensive drugs, lipid‐lowering drugs, antidepressants, non‐steroidal anti‐inflammatory drugs \[NSAIDs\] and weight‐loss drugs); and metabolic markers within 12 months before or on the index date (glycated haemoglobin \[HbA1C\], glucose, triglycerides, total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure and high‐sensitivity C‐reactive protein). Comorbid conditions were defined according to ICM‐9‐CM codes, medication use, or laboratory results using ICD‐9‐CM codes or algorithms from published studies and clinical guidelines ([Table S1](#osp446-supinf-0001){ref-type="supplementary-material"}).

Study outcomes {#osp446-sec-0009}
--------------

The outcome variable for this analysis was the prescription of pharmacotherapy for weight loss within 12 months after the index date. Weight‐loss drugs that were considered included benzphetamine, diethylpropion, orlistat, phendimetrazine, phentermine, sibutramine, lorcaserin and phentermine/topiramate. Bupropion/naltrexone and liraglutide 3.0 mg were not considered in this analysis, as they were approved in 2014, which was outside of the study period.

Statistical analysis {#osp446-sec-0010}
--------------------

Patient characteristics were analysed using descriptive statistics in the overall study population and were stratified by the use of pharmacotherapy for weight loss within 12 months after the index date. Tests for differences between patients who received pharmacotherapy (the treated group) and those who did not receive pharmacotherapy (the untreated group) were performed using a chi‐square test or the Fisher\'s exact test for comparing the frequencies of categorical variables, and the Wilcoxon rank‐sum test for comparing the median values of continuous variables between these two groups. For variables with unknown, undetermined, not entered, or missing data, only non‐missing values were included in tests for statistical significance.

To identify patient characteristics at baseline predictive of the use of pharmacotherapy for weight loss, a logistic regression analysis was conducted to estimate the odds ratios and their 95% confidence intervals with the inclusion of the following variables: BMI categories at index (≥27 to \<30 with hypertension, dyslipidemia, or type 2 diabetes, ≥30 to \<35, ≥35 to \<40, ≥40 kg m^−2^), age at index (18--34, 35--49, 50--64, ≥65 years), gender (male, female, unknown), race (white, black or African American, Hispanic, Asian, American Indian/multi/other, unknown/undetermined/not entered/missing), region (Midwest, Northeast, South, West), insurance (commercial, Medicare, Medicare \[others\], Medicaid, self‐pay, Tricare/Railroad/United Mine Workers, unknown/missing), smoking status (no, yes), hypertension (no, yes), dyslipidemia (no, yes), type 2 diabetes (no, yes), osteoarthritis (no, yes), coronary heart disease (no, yes), congestive heart failure (no, yes), cardiac dysrhythmia (no, yes), stroke (no, yes), chronic kidney disease (no, yes), depression (no, yes), anxiety (no, yes), sleep apnea (no, yes), GERD (no, yes), chronic obstructive pulmonary disease (no, yes), asthma (no, yes), anti‐diabetic drugs (no, yes), anti‐hypertensive drugs (no, yes), lipid‐lowering drugs (no, yes), antidepressants (no, yes), NSAIDs (no, yes) and weight‐loss drugs (no, yes). A backward stepwise selection procedure was used to identify the variables for the final multivariable model, and the variables with *P* values of \> 0.05 were excluded from the model.

All tests were two‐sided, and data were analyzed using [sas]{.smallcaps} software, version 9.2 (SAS Institute, Cary, NC, USA).

Results {#osp446-sec-0011}
=======

A total of 25,704,135 patients had BMI measurements at any time in the database, and 1,835,541 patients were included in the analysis after the application of the inclusion and exclusion criteria (Figure [1](#osp446-fig-0001){ref-type="fig"}). The median BMI value of patients at index was 31.3 kg m^−2^ (Table [1](#osp446-tbl-0001){ref-type="table-wrap"}); 20% of patients had a BMI of ≥27 to \<30 kg m^−2^ with hypertension, dyslipidemia, or type 2 diabetes; 55% of patients had a BMI of ≥30 to \<35 kg m^−2^; 15% of patients had a BMI of ≥35 to \<40 kg m^−2^; and 11% of patients had a BMI of ≥40 kg m^−2^ (Figure [1](#osp446-fig-0001){ref-type="fig"}). Of the study population, 58.3% were women and the mean baseline age of patients was 51.8 ± 16.5 years. Comorbidities were common (hypertension \[55.4%\], dyslipidemia \[36.1%\], and type 2 diabetes \[13.4%\]) and the use of concomitant medications was also common (anti‐hypertensive drugs \[19.3%\], lipid‐lowering drugs \[17.9%\], antidepressants \[14.2%\], NSAIDs \[12.1%\] and anti‐diabetic drugs \[7.8%\]) at baseline. However, the use of weight‐loss drugs at baseline was rare (0.6%).

![Flow diagram of study population selection.](OSP4-2-104-g001){#osp446-fig-0001}

###### 

Characteristics of patients potentially eligible for pharmacotherapy for weight loss

  Characteristic[\*](#osp446-note-0001){ref-type="fn"}                                                      Overall (*n* = 1,835,541)   Treated with pharmacotherapy for weight loss within 12 months after the index date (*n* = 11,862)   Untreated with pharmacotherapy for weight loss within 12 months after the index date (*n* = 1,823,679)   *P* value[†](#osp446-note-0002){ref-type="fn"}
  --------------------------------------------------------------------------------------------------------- --------------------------- --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------
  Weight at index, kg                                                                                                                                                                                                                                                                                                                                
  Median (25th, 75th percentile)                                                                            90.7 (80.7, 103.0)          93.4 (83.0, 110.0)                                                                                  90.7 (80.7, 103.0)                                                                                       \<0.0001
  Body mass index at index, kg m^−2^                                                                                                                                                                                                                                                                                                                 
  Median (25th, 75th percentile)                                                                            31.3 (30.1, 35.1)           33.6 (30.8, 39.2)                                                                                   31.3 (30.1, 35.1)                                                                                        \<0.0001
  Body mass index categories at index, *n* (%)                                                                                                                                                                                                                                                                                                       \<0.0001
  ≥27 to \<30 kg m^−2^ with hypertension, dyslipidemia, or type 2 diabetes                                  368,653 (20.1)              752 (6.3)                                                                                           367,901 (20.2)                                                                                           
  ≥30 to \<35 kg m^−2^                                                                                      1,001,261 (54.5)            6099 (51.4)                                                                                         995,162 (54.6)                                                                                           
  ≥35 to \<40 kg m^−2^                                                                                      267,747 (14.6)              2364 (19.9)                                                                                         265,383 (14.6)                                                                                           
  ≥40 kg m^−2^                                                                                              197,880 (10.8)              2647 (22.3)                                                                                         195,233 (10.7)                                                                                           
  Age at index, years                                                                                                                                                                                                                                                                                                                                
  Median (25th, 75th percentile)                                                                            52.0 (40.0, 64.0)           42.0 (33.0, 51.0)                                                                                   52.0 (40.0, 65.0)                                                                                        \<0.0001
  Age groups at index, *n* (%)                                                                                                                                                                                                                                                                                                                       \<0.0001
  18--34 years                                                                                              323,882 (17.7)              3589 (30.3)                                                                                         320,293 (17.6)                                                                                           
  35--49 years                                                                                              479,923 (26.2)              4753 (40.1)                                                                                         475,170 (26.1)                                                                                           
  50--64 years                                                                                              573,802 (31.3)              2863 (24.1)                                                                                         570,939 (31.3)                                                                                           
  ≥65 years                                                                                                 457,934 (25.0)              657 (5.5)                                                                                           457,277 (25.1)                                                                                           
  Gender, *n* (%)[‡](#osp446-note-0003){ref-type="fn"}                                                                                                                                                                                                                                                                                               \<0.0001
  Male                                                                                                      764,624 (41.7)              1860 (15.7)                                                                                         762,764 (41.8)                                                                                           
  Female                                                                                                    1,070,719 (58.3)            10,001 (84.3)                                                                                       1,060,718 (58.2)                                                                                         
  Race, *n* (%)[‡](#osp446-note-0003){ref-type="fn"}                                                                                                                                                                                                                                                                                                 \<0.0001
  White                                                                                                     1,056,812 (85.3)            7363 (85.5)                                                                                         1,049,449 (85.3)                                                                                         
  Black or African American                                                                                 132,366 (10.7)              932 (10.8)                                                                                          131,434 (10.7)                                                                                           
  Hispanic                                                                                                  19,334 (1.6)                167 (1.9)                                                                                           19,167 (1.6)                                                                                             
  Asian                                                                                                     12,119 (1.0)                58 (0.7)                                                                                            12,061 (1.0)                                                                                             
  American Indian/multi/other                                                                               18,150 (1.5)                90 (1.1)                                                                                            18,060 (1.5)                                                                                             
  Region, *n* (%)                                                                                                                                                                                                                                                                                                                                    \<0.0001
  Midwest                                                                                                   475,237 (25.9)              3057 (25.8)                                                                                         472,180 (25.9)                                                                                           
  Northeast                                                                                                 502,212 (27.4)              1888 (15.9)                                                                                         500,324 (27.4)                                                                                           
  South                                                                                                     593,853 (32.4)              5184 (43.7)                                                                                         588,669 (32.3)                                                                                           
  West                                                                                                      264,239 (14.4)              1733 (14.6)                                                                                         262,506 (14.4)                                                                                           
  Insurance, *n* (%)[‡](#osp446-note-0003){ref-type="fn"}                                                                                                                                                                                                                                                                                            \<0.0001
  Commercial                                                                                                595,161 (50.5)              4642 (70.1)                                                                                         590,519 (50.4)                                                                                           
  Medicare                                                                                                  455,333 (38.6)              1264 (19.1)                                                                                         454,069 (38.7)                                                                                           
  Medicare (others[§](#osp446-note-0004){ref-type="fn"})                                                    50,201 (4.3)                168 (2.5)                                                                                           50,033 (4.3)                                                                                             
  Medicaid                                                                                                  35,262 (3.0)                306 (4.6)                                                                                           34,956 (3.0)                                                                                             
  Self‐pay                                                                                                  36,630 (3.1)                213 (3.2)                                                                                           36,417 (3.1)                                                                                             
  Tricare/Railroad/United Mine Workers                                                                      6,903 (0.6)                 28 (0.4)                                                                                            6,875 (0.6)                                                                                              
  Smokers, *n* (%)                                                                                          78,493 (4.3)                524 (4.4)                                                                                           77,969 (4.3)                                                                                             0.44[║](#osp446-note-0005){ref-type="fn"}
  Comorbid conditions at baseline, *n* (%)                                                                                                                                                                                                                                                                                                           
  Hypertension                                                                                              1,016,290 (55.4)            5688 (48.0)                                                                                         1,010,602 (55.4)                                                                                         \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Dyslipidemia                                                                                              663,015 (36.1)              3765 (31.7)                                                                                         659,250 (36.2)                                                                                           \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Type 2 diabetes[¶](#osp446-note-0006){ref-type="fn"}                                                      246,539 (13.4)              1382 (11.7)                                                                                         245,157 (13.4)                                                                                           \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Osteoarthritis[¶](#osp446-note-0006){ref-type="fn"}                                                       166,869 (9.1)               903 (7.6)                                                                                           165,966 (9.1)                                                                                            \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Coronary heart disease[¶](#osp446-note-0006){ref-type="fn"}                                               62,024 (3.4)                121 (1.0)                                                                                           61,903 (3.4)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Congestive heart failure[¶](#osp446-note-0006){ref-type="fn"}                                             35,274 (1.9)                73 (0.6)                                                                                            35,201 (1.9)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Cardiac dysrhythmia[¶](#osp446-note-0006){ref-type="fn"}                                                  89,946 (4.9)                216 (1.8)                                                                                           89,730 (4.9)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Stroke[¶](#osp446-note-0006){ref-type="fn"}                                                               46,299 (2.5)                89 (0.8)                                                                                            46,210 (2.5)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Chronic kidney disease[¶](#osp446-note-0006){ref-type="fn"}                                               47,429 (2.6)                100 (0.8)                                                                                           47,329 (2.6)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Depression                                                                                                51,161 (2.8)                821 (6.9)                                                                                           50,340 (2.8)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Anxiety                                                                                                   55,365 (3.0)                605 (5.1)                                                                                           54,760 (3.0)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Sleep apnea                                                                                               29,984 (1.6)                260 (2.2)                                                                                           29,724 (1.6)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Gastroesophageal reflux disease                                                                           88,902 (4.8)                652 (5.5)                                                                                           88,250 (4.8)                                                                                             0.001[║](#osp446-note-0005){ref-type="fn"}
  Chronic obstructive pulmonary disease[¶](#osp446-note-0006){ref-type="fn"}                                66,517 (3.6)                253 (2.1)                                                                                           66,264 (3.6)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Asthma                                                                                                    44,404 (2.4)                390 (3.3)                                                                                           44,014 (2.4)                                                                                             \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Comedications at baseline, *n* (%)                                                                                                                                                                                                                                                                                                                 
  Anti‐hypertensive drugs                                                                                   354,797 (19.3)              1918 (16.2)                                                                                         352,879 (19.4)                                                                                           \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Lipid‐lowering drugs                                                                                      328,846 (17.9)              1540 (13.0)                                                                                         327,306 (18.0)                                                                                           \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Anti‐diabetic drugs                                                                                       143,000 (7.8)               1074 (9.1)                                                                                          141,926 (7.8)                                                                                            \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Antidepressants                                                                                           260,142 (14.2)              3653 (30.8)                                                                                         256,489 (14.1)                                                                                           \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Non‐steroidal anti‐inflammatory drugs                                                                     221,356 (12.1)              2579 (21.7)                                                                                         218,777 (12.0)                                                                                           \<0.0001[║](#osp446-note-0005){ref-type="fn"}
  Weight‐loss drugs                                                                                         10,685 (0.6)                4474 (37.7)                                                                                         6211 (0.3)                                                                                               \<0.0001
  Metabolic markers at baseline[‡](#osp446-note-0003){ref-type="fn"}                                                                                                                                                                                                                                                                                 
  Glycated haemoglobin, %                                                                                                                                                                                                                                                                                                                            
  *n*                                                                                                       224,683                     1,332                                                                                               223,351                                                                                                  
  Median (25th, 75th percentile)                                                                            6.5 (5.9, 7.6)              6.3 (5.7, 7.4)                                                                                      6.5 (5.9, 7.6)                                                                                           \<0.0001
  Glucose, mg dL^−1^                                                                                                                                                                                                                                                                                                                                 
  *n*                                                                                                       68,956                      474                                                                                                 68,482                                                                                                   
  Median (25th, 75th percentile)                                                                            100 (91, 118)               97.5 (89, 111)                                                                                      100 (91, 118)                                                                                            0.001
  Triglycerides, mg dL^−1^                                                                                                                                                                                                                                                                                                                           
  *n*                                                                                                       442,186                     2786                                                                                                439,400                                                                                                  
  Median (25th, 75th percentile)                                                                            134 (94, 192)               139 (96, 197)                                                                                       134 (94, 192)                                                                                            0.03
  Total cholesterol, mg dL^−1^                                                                                                                                                                                                                                                                                                                       
  *n*                                                                                                       670,077                     4149                                                                                                665,928                                                                                                  
  Median (25th, 75th percentile)                                                                            190 (164, 219)              197 (173, 226)                                                                                      190 (163, 219)                                                                                           \<0.0001
  Low‐density lipoprotein cholesterol, mg dL^−1^                                                                                                                                                                                                                                                                                                     
  *n*                                                                                                       487,835                     3123                                                                                                484,712                                                                                                  
  Median (25th, 75th percentile)                                                                            111 (88, 136)               117 (94, 140)                                                                                       111 (88, 136)                                                                                            \<0.0001
  High‐density lipoprotein cholesterol, mg dL^−1^                                                                                                                                                                                                                                                                                                    
  *n*                                                                                                       648,504                     3923                                                                                                644,581                                                                                                  
  Median (25th, 75th percentile)                                                                            47 (39, 57)                 49 (41, 59)                                                                                         47 (39, 57)                                                                                              \<0.0001
  Systolic blood pressure, mmHg                                                                                                                                                                                                                                                                                                                      
  *n*                                                                                                       1,759,558                   11,753                                                                                              1,747,805                                                                                                
  Median (25th, 75th percentile)                                                                            128 (120, 140)              124 (117, 134)                                                                                      128 (120, 140)                                                                                           \<0.0001
  Diastolic blood pressure, mmHg                                                                                                                                                                                                                                                                                                                     
  *n*                                                                                                       1,758,964                   11,752                                                                                              1,747,212                                                                                                
  Median (25th, 75th percentile)                                                                            80 (70, 84)                 80 (72, 84)                                                                                         80 (70, 84)                                                                                              0.11
  High‐sensitivity C‐reactive protein, mg L^−1^                                                                                                                                                                                                                                                                                                      
  *n*                                                                                                       2944                        13                                                                                                  2931                                                                                                     
  Median (25th, 75th percentile)                                                                            3.8 (1.4, 10.6)             4.0 (1.7, 16.1)                                                                                     3.8 (1.4, 10.6)                                                                                          0.82
  Bariatric surgery,[¶](#osp446-note-0006){ref-type="fn"}, [\#](#osp446-note-0007){ref-type="fn"} *n* (%)   1869 (0.1)                  16 (0.1)                                                                                            1853 (0.1)                                                                                               0.25

Within 12 months before or on the index date except as noted.

*P* values were from the chi‐square test or Fisher\'s exact test for comparing the frequencies of categorical variables between the treated group and the untreated group, and from the Wilcoxon rank‐sum test for comparing the median values of continuous variables between the two groups. For variables with unknown, undetermined, not entered, or missing data, only those with values were included in tests for statistical significance.

Including only non‐missing data.

Including Medicare part A, part C, private, or supplemental insurance.

Fisher\'s exact test.

Any time before or on the index date.

Within 12 months after the index date.

There were also few patients who received pharmacotherapy for weight loss within 12 months after the index date (0.7%; *n* = 11,862). The percentage of patients who received pharmacotherapy within 12 months after the index date increased with increasing baseline BMI categories (Figure [2](#osp446-fig-0002){ref-type="fig"}). Among patients who received pharmacotherapy within 12 months after the index date, phentermine was the most frequently prescribed weight‐loss drug (62.9%), followed by orlistat (19.1%), sibutramine (14.7%), phendimetrazine (1.8%), diethylpropion (1.3%) and benzphetamine (0.2%). Lorcaserin and phentermine/topiramate, which were approved in the summer of 2012 (slightly overlapping with the study period), were not present in this analysis.

![Use of pharmacotherapy for weight loss within 12 months after the index date among patients potentially eligible for pharmacotherapy for weight loss. Note: \*BMI ≥27 to \<30 kg m^−2^ (overweight) with ≥1 obesity‐associated comorbidity (hypertension, dyslipidemia, or type 2 diabetes).](OSP4-2-104-g002){#osp446-fig-0002}

Compared with those who did not receive pharmacotherapy for weight loss within 12 months after the index date, patients who received treatment were predominantly female (84.3% vs. 58.2%), heavier (median BMI, 33.6 vs. 31.3 kg m^−2^), approximately 10 years younger (median age, 42 vs. 52 years), more commercially insured (70.1% vs. 50.4%) and were more likely to live in the Southern region of the USA (43.7% vs. 32.3%) at baseline (all *P* values \< 0.0001) (Table [1](#osp446-tbl-0001){ref-type="table-wrap"}). The percentage of female patients decreased with increasing baseline BMI categories among patients who received pharmacotherapy, but increased with increasing baseline BMI categories among those who did not receive pharmacotherapy (Figure [3](#osp446-fig-0003){ref-type="fig"}a). Patients who received pharmacotherapy were younger than their counterparts who did not receive pharmacotherapy, and this trend was observed across all baseline BMI categories (Figure [3](#osp446-fig-0003){ref-type="fig"}b).

![Gender and age distribution of patients potentially eligible for pharmacotherapy for weight loss, a. Gender distribution of patients, b. Mean age at index of patients. Note: \*BMI ≥27 to \<30 kg m^−2^ (overweight) with ≥1 obesity‐associated comorbidity (hypertension, dyslipidemia, or type 2 diabetes).](OSP4-2-104-g003){#osp446-fig-0003}

Moreover, patients who received pharmacotherapy for weight loss within 12 months after the index date had a relatively lower percentage of hypertension, dyslipidemia, type 2 diabetes, osteoarthritis, cardiovascular diseases (coronary heart disease, congestive heart failure, cardiac dysrhythmia and stroke), chronic kidney disease and chronic obstructive pulmonary disease, but had a higher percentage of depression, anxiety, sleep apnea, GERD and asthma at baseline (all *P* values \< 0.0001 except for GERD \[*P* = 0.001\]) (Table [1](#osp446-tbl-0001){ref-type="table-wrap"}). Additionally, at baseline, these patients received relatively fewer anti‐hypertensive drugs and lipid‐lowering drugs, but slightly more anti‐diabetic medications (all *P* values \< 0.0001). Further, use of antidepressants (30.8% vs. 14.1%), NSAIDs (21.7% vs. 12.0%) and weight‐loss drugs (37.7% vs. 0.3%) at baseline was markedly higher in patients who received pharmacotherapy for weight loss within 12 months after the index date than those who did not (all *P* values \< 0.0001). Patients who received pharmacotherapy for weight loss within 12 months after the index date had slightly lower levels of HbA1C, glucose and systolic blood pressure, but slightly higher levels of triglycerides, total cholesterol, low‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol at baseline (all *P* values \< 0.0001 except for glucose \[*P* = 0.001\] and triglyceride \[*P* = 0.03\]).

In multivariable analysis using a backward stepwise selection procedure, baseline patient characteristics that were significantly associated with the use of pharmacotherapy for weight loss in the following 12 months (positively or negatively) included BMI, age, gender, race, region, insurance, dyslipidemia, depression, osteoarthritis, sleep apnea, type 2 diabetes, cardiovascular disease, chronic kidney disease, use of anti‐hypertensive drugs, anti‐diabetic drugs, antidepressants, NSAIDs, or weight‐loss drugs (Table [2](#osp446-tbl-0002){ref-type="table-wrap"}). Use of weight‐loss drugs at baseline was the strongest predictor of future weight‐loss drug use -- those who used weight‐loss drugs at baseline were 99 times more likely to use weight‐loss drugs in the next 12 months (Table [2](#osp446-tbl-0002){ref-type="table-wrap"}).

###### 

Patient characteristics at baseline that were predictive of the use of pharmacotherapy for weight loss within 12 months after the index date in the multivariable logistic regression analysis

  Characteristic[\*](#osp446-note-0008){ref-type="fn"}              Odds ratio[†](#osp446-note-0009){ref-type="fn"}   95% confidence interval[†](#osp446-note-0009){ref-type="fn"}   *P* value[†](#osp446-note-0009){ref-type="fn"}
  ----------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------
  BMI categories at index, kg m^−2^                                                                                                                                                  
  ≥27 to \<30 with hypertension, dyslipidemia, or type 2 diabetes   0.51                                              (0.47--0.56)                                                   \<0.0001
  ≥30 to \<35                                                       1.00                                                                                                             
  ≥35 to \<40                                                       1.32                                              (1.25--1.39)                                                   \<0.0001
  ≥40                                                               1.56                                              (1.48--1.65)                                                   \<0.0001
  Age groups at index, years                                                                                                                                                         
  18--34                                                            1.00                                                                                                             
  35--49                                                            0.83                                              (0.79--0.88)                                                   \<0.0001
  50--64                                                            0.50                                              (0.47--0.53)                                                   \<0.0001
  ≥65                                                               0.22                                              (0.20--0.25)                                                   \<0.0001
  Gender                                                                                                                                                                             
  Male                                                              1.00                                                                                                             
  Female                                                            2.58                                              (2.44--2.72)                                                   \<0.0001
  Unknown                                                           1.36                                              (0.16--11.46)                                                  0.78
  Race                                                                                                                                                                               
  White                                                             1.00                                                                                                             
  Black or African American                                         0.75                                              (0.69--0.81)                                                   \<0.0001
  Hispanic                                                          1.15                                              (0.97--1.37)                                                   0.11
  Asian                                                             0.92                                              (0.70--1.21)                                                   0.55
  American Indian/multi/other                                       0.62                                              (0.50--0.78)                                                   \<0.0001
  Unknown/undetermined/not entered/missing                          0.79                                              (0.76--0.83)                                                   \<0.0001
  Region                                                                                                                                                                             
  Midwest                                                           1.00                                                                                                             
  Northeast                                                         0.59                                              (0.55--0.63)                                                   \<0.0001
  South                                                             1.21                                              (1.15--1.27)                                                   \<0.0001
  West                                                              1.10                                              (1.03--1.18)                                                   0.004
  Insurance                                                                                                                                                                          
  Commercial                                                        1.00                                                                                                             
  Medicare                                                          0.74                                              (0.69--0.80)                                                   \<0.0001
  Medicare (others[‡](#osp446-note-0010){ref-type="fn"})            0.85                                              (0.72--1.01)                                                   0.07
  Medicaid                                                          0.82                                              (0.72--0.94)                                                   0.003
  Self‐pay                                                          0.67                                              (0.58--0.78)                                                   \<0.0001
  Tricare/Railroad/United Mine Workers                              0.83                                              (0.55--1.25)                                                   0.37
  Unknown/missing                                                   0.99                                              (0.95--1.04)                                                   0.74
  Comorbid conditions at baseline, *n* (%)                                                                                                                                           
  Dyslipidemia                                                                                                                                                                       
  No                                                                1.00                                                                                                             
  Yes                                                               1.18                                              (1.12--1.24)                                                   \<0.0001
  Depression                                                                                                                                                                         
  No                                                                1.00                                                                                                             
  Yes                                                               1.15                                              (1.05--1.26)                                                   0.003
  Osteoarthritis[§](#osp446-note-0011){ref-type="fn"}                                                                                                                                
  No                                                                1.00                                                                                                             
  Yes                                                               1.11                                              (1.02--1.20)                                                   0.01
  Sleep apnea                                                                                                                                                                        
  No                                                                1.00                                                                                                             
  Yes                                                               1.44                                              (1.25--1.66)                                                   \<0.0001
  Type 2 diabetes[§](#osp446-note-0011){ref-type="fn"}                                                                                                                               
  No                                                                1.00                                                                                                             
  Yes                                                               0.89                                              (0.80--0.99)                                                   0.03
  Coronary heart disease[§](#osp446-note-0011){ref-type="fn"}                                                                                                                        
  No                                                                1.00                                                                                                             
  Yes                                                               0.73                                              (0.60--0.89)                                                   0.002
  Congestive heart failure[§](#osp446-note-0011){ref-type="fn"}                                                                                                                      
  No                                                                1.00                                                                                                             
  Yes                                                               0.69                                              (0.53--0.88)                                                   0.003
  Cardiac dysrhythmia[§](#osp446-note-0011){ref-type="fn"}                                                                                                                           
  No                                                                1.00                                                                                                             
  Yes                                                               0.77                                              (0.67--0.90)                                                   0.0006
  Stroke[§](#osp446-note-0011){ref-type="fn"}                                                                                                                                        
  No                                                                1.00                                                                                                             
  Yes                                                               0.74                                              (0.59--0.92)                                                   0.006
  Chronic kidney disease[§](#osp446-note-0011){ref-type="fn"}                                                                                                                        
  No                                                                1.00                                                                                                             
  Yes                                                               0.78                                              (0.63--0.96)                                                   0.02
  Comedications at baseline, *n* (%)                                                                                                                                                 
  Anti‐hypertensive drugs                                                                                                                                                            
  No                                                                1.00                                                                                                             
  Yes                                                               1.07                                              (1.00--1.13)                                                   0.04
  Anti‐diabetic drugs                                                                                                                                                                
  No                                                                1.00                                                                                                             
  Yes                                                               1.25                                              (1.11--1.41)                                                   0.0002
  Antidepressants                                                                                                                                                                    
  No                                                                1.00                                                                                                             
  Yes                                                               1.65                                              (1.57--1.74)                                                   \<0.0001
  Non‐steroidal anti‐inflammatory drugs                                                                                                                                              
  No                                                                1.00                                                                                                             
  Yes                                                               1.38                                              (1.31--1.45)                                                   \<0.0001
  Weight‐loss drugs                                                                                                                                                                  
  No                                                                1.00                                                                                                             
  Yes                                                               98.96                                             (94.38--103.77)                                                \<0.0001

Within 12 months before or on the index date except as noted.

Logistic regression was conducted with the inclusion of the variables for demographic and clinical characteristics at baseline, including BMI categories at index (≥27 to \<30 with hypertension, dyslipidemia, or type 2 diabetes, ≥30 to \<35, ≥35 to \<40, ≥40 kg m^−2^), age at index (18--34, 35--49, 50--64, ≥65 years), gender (male, female, unknown), race (white, black or African American, Hispanic, Asian, American Indian/multi/other, unknown/undetermined/not entered/missing), region (Midwest, Northeast, South, West), insurance (commercial, Medicare, Medicare \[others\], Medicaid, self‐pay, Tricare/Railroad/United Mine Workers, unknown/missing), smoking status (no, yes), hypertension (no, yes), dyslipidemia (no, yes), type 2 diabetes (no, yes), osteoarthritis (no, yes), coronary heart disease (no, yes), congestive heart failure (no, yes), cardiac dysrhythmia (no, yes), stroke (no, yes), chronic kidney disease (no, yes), depression (no, yes), anxiety (no, yes), sleep apnea (no, yes), gastroesophageal reflux disease (no, yes), chronic obstructive pulmonary disease (no, yes), asthma (no, yes), anti‐diabetic drugs (no, yes), anti‐hypertensive drugs (no, yes), lipid‐lowering drugs (no, yes), antidepressants (no, yes), non‐steroidal anti‐inflammatory drugs (no, yes) and weight‐loss drugs (no, yes). A backward stepwise selection procedure was used to identify the variables for the final multivariable model, and the variables with *P* values of \> 0.05 were excluded from the model. Use of pharmacotherapy for weight loss within 12 months after the index date (no, yes) was the outcome variable.

Including Medicare part A, part C, private, or supplemental insurance.

Any time before or on the index date

BMI, body mass index.

Discussion {#osp446-sec-0012}
==========

In patients with overweight and ≥1 obesity‐associated comorbidity or with obesity (who were therefore potentially eligible for pharmacotherapy for weight loss) in the primary care setting in the USA, comorbidities were common; however, pharmacotherapy use for weight loss within 12 months after the index date was infrequent (0.7%). In this study, patients who received pharmacotherapy were heavier, younger, predominantly female and more commercially insured at baseline compared with those who did not receive pharmacotherapy. Among the comedications evaluated, patients who received pharmacotherapy for weight loss were more commonly on antidepressants, NSAIDs, or weight‐loss drugs, but were less frequently to have a personal history of cardiovascular disease or chronic kidney disease at baseline. Phentermine was the most frequently prescribed weight‐loss drug (62.9%) among those who were prescribed weight‐loss medications. Prior use of weight‐loss drugs was the strongest predictor of future weight‐loss drug use as measured within 12 months after the index date.

Data on the characteristics of real‐world patients eligible for weight‐loss drugs have been limited. Consistent with the present study using prescription data in a US primary care setting, data from two US national surveys have also indicated that the use of pharmacotherapy for weight loss among eligible patients is low [8](#osp446-bib-0008){ref-type="ref"}, [9](#osp446-bib-0009){ref-type="ref"}. In a retrospective cross‐sectional analysis of pharmacy data from the 2002--2007 US Medical Expenditure Panel Survey, only 0.61% of eligible patients used weight‐loss drugs [8](#osp446-bib-0008){ref-type="ref"}. In another retrospective cross‐sectional analysis of self‐reported data from the 2007--2008 National Health and Nutrition Examination Survey, only 2.2% of eligible patients reported the use of prescription weight‐loss drugs, and 3.7% reported the use of non‐prescription weight‐loss drugs in the past year [9](#osp446-bib-0009){ref-type="ref"}. Similarly, an analysis of US outpatient weight‐loss drug use using the Intercontinental Marketing Services (IMS) databases has shown that only approximately 2.74 million patients used weight‐loss drugs in the USA in 2011, with the majority of patients receiving phentermine (2.43 million; 89%) [10](#osp446-bib-0010){ref-type="ref"}.

The low utilization of weight‐loss drugs among patients eligible for pharmacotherapy for weight loss in the USA could be ascribed to a number of factors, such as moderate weight‐loss effects, costs and limited insurance coverage for weight‐loss drugs and safety concerns. In clinical trials, when used with lifestyle interventions, weight‐loss drugs provided additional weight loss that ranged from approximately 3% to 9% of their initial weight at 1 year compared with placebo [6](#osp446-bib-0006){ref-type="ref"}. However, the expectation for weight loss effects in patients is often higher [11](#osp446-bib-0011){ref-type="ref"}. Although weight‐loss drugs significantly improve cardiovascular risk factors such as insulin sensitivity, glycemic control, dyslipidemia, hypertension and chronic inflammation in patients with overweight or obesity [12](#osp446-bib-0012){ref-type="ref"}, [13](#osp446-bib-0013){ref-type="ref"}, [14](#osp446-bib-0014){ref-type="ref"}, [15](#osp446-bib-0015){ref-type="ref"}, [16](#osp446-bib-0016){ref-type="ref"}, these health benefits may not be immediately obvious to patients. Also, no weight‐loss drug has been demonstrated to decrease cardiovascular morbidity or mortality [6](#osp446-bib-0006){ref-type="ref"}. Additionally, patients often prefer self‐management or over‐the‐counter options for weight control such as dietary changes, exercise, diet, or exercise weight‐loss programmes and dietary and herbal weight‐loss supplements [11](#osp446-bib-0011){ref-type="ref"}. As mentioned previously, more patients who were eligible for pharmacotherapy reported the use of non‐prescription weight‐loss drugs (3.7%) than prescription weight‐loss drugs (2.2%) in the past year in the USA [9](#osp446-bib-0009){ref-type="ref"}. Costs may also be a barrier, as most health plans in the USA provide limited or no coverage for weight‐loss drugs. The Medicare prescription drug programme, for example, does not cover weight‐loss drugs [17](#osp446-bib-0017){ref-type="ref"}. An analysis by Hampp *et al.*, found that weight‐loss drugs were mainly paid for with cash [10](#osp446-bib-0010){ref-type="ref"}. As shown in this study and in the Hampp study [10](#osp446-bib-0010){ref-type="ref"}, phentermine was the most prescribed weight‐loss medication in the USA. This may be due, at least in part, to its low cost and long clinical experience compared with other weight‐loss drugs [6](#osp446-bib-0006){ref-type="ref"}, [10](#osp446-bib-0010){ref-type="ref"}. Another contributing factor to the low utilization of pharmacotherapy for weight loss may be safety concerns, including the historical safety issues with weight‐loss drugs such as fenfluramine (part of the fen‐phen combination) [18](#osp446-bib-0018){ref-type="ref"}.

This real‐world study in the primary care setting, along with randomized clinical trials [12](#osp446-bib-0012){ref-type="ref"}, [13](#osp446-bib-0013){ref-type="ref"}, [14](#osp446-bib-0014){ref-type="ref"}, [15](#osp446-bib-0015){ref-type="ref"}, [16](#osp446-bib-0016){ref-type="ref"} and other observational studies [8](#osp446-bib-0008){ref-type="ref"}, [9](#osp446-bib-0009){ref-type="ref"}, [10](#osp446-bib-0010){ref-type="ref"}, have indicated that most users of prescription weight‐loss drugs were predominantly women of a relatively younger age than non‐users. This may be due, at least in part, to the fact that women, especially younger women, are more conscious of body weight, size and self‐image [19](#osp446-bib-0019){ref-type="ref"}, [20](#osp446-bib-0020){ref-type="ref"}, [21](#osp446-bib-0021){ref-type="ref"}. The lower likelihood of pharmacotherapy use for weight loss in the elderly population might also be related to costs and the lack of Medicare coverage for weight‐loss drugs. This hypothesis is supported by the finding in this study, which showed that patients enrolled in Medicare were less likely to use pharmacotherapy for weight loss compared with patients who were commercially insured.

The relationship between obesity and depression has been suggested to be bidirectional -- obesity leads to depression, and conversely, depression results in obesity [22](#osp446-bib-0022){ref-type="ref"}. The present study has shown that antidepressant use was not uncommon in patients with overweight or obesity and those patients who used antidepressants or had depression were also more likely to use pharmacotherapy for weight loss. These findings further suggest that there is a complex relationship between obesity and depression.

Obesity and chronic pain often co‐exist [23](#osp446-bib-0023){ref-type="ref"}. NSAIDs are commonly used for the management of chronic pain. Obesity has been shown to be associated with an increased risk of chronic pain, including low back pain, joint pain, headaches, fibromyalgia, widespread pain, abdominal pain, pelvic pain and neuropathic pain [23](#osp446-bib-0023){ref-type="ref"}. Obesity is a risk factor of osteoarthritis and is also associated with the severity and progression of the disease [23](#osp446-bib-0023){ref-type="ref"}, [24](#osp446-bib-0024){ref-type="ref"}. Studies have shown that the frequency of chronic pain and osteoarthritis increases with increasing BMI [23](#osp446-bib-0023){ref-type="ref"}, [24](#osp446-bib-0024){ref-type="ref"}. In this study, the finding that patients with overweight or obesity who took NSAIDs were more likely to use pharmacotherapy for weight loss suggests that patients with chronic pain conditions might be more motivated to lose weight for reducing obesity‐associated chronic pain.

Obesity is strongly associated with an increased prevalence of sleep apnea [25](#osp446-bib-0025){ref-type="ref"}, [26](#osp446-bib-0026){ref-type="ref"}. Sleep apnea severely impairs health‐related quality of life [26](#osp446-bib-0026){ref-type="ref"}. Weight loss has been shown to reduce the severity of sleep apnea [25](#osp446-bib-0025){ref-type="ref"}, [26](#osp446-bib-0026){ref-type="ref"}. The present study has shown that patients with overweight or obesity who had sleep apnea were more likely to use pharmacotherapy for weight loss, suggesting that patients with sleep apnea might be more motivated to lose weight to help control sleep apnea.

This study has several strengths, including a large sample size and the utilization of real‐world data from electronic medical records in the primary care setting. Additionally, there were little or no missing data on gender and age, two key covariates. However, this retrospective observational study also has some limitations. Although a multivariable analysis was performed to control for potential confounding of measured covariates, the residual confounding from confounders with measurement errors and the potential confounding by unmeasured covariates such as socioeconomic factors, use of non‐prescription weight‐loss medications and participation in dietary and physical activity programmes or time‐dependent covariates cannot be excluded. The missing‐indicator method was used for those covariates with missing data. The possibility that missing data in covariates might potentially influence the patterns of patient characteristics also cannot be excluded.

In summary, the findings from this large study suggest that few eligible patients in the primary care setting in the USA receive pharmacotherapy for weight loss. Patients who received pharmacotherapy tended to be heavier, younger, predominantly female, more commercially insured and used more antidepressants and NSAIDs than those who did not receive pharmacotherapy.
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